BBS 10 24 24 HeartSciences CEO Andrew discusses MyoVista wavECG & MyoVi... https://lnkd.in/gRXAJjDg via @YouTube
HeartSciences (NASDAQ:HSCS)
医疗设备制造业
Southlake，Texas 1,112 位关注者
Millions of ECGs are performed every week with technology that hasn't changed in 50 years. We intend to change that.
关于我们
Heart disease is a global pandemic affecting 26 million worldwide and increasing in prevalence. More effective front-line tools are needed to identify patients earlier while lowering costs for health systems. Current conventional ECG/EKG testing, the key front-line tool, has significant limitations for detecting 2 out of 3 categories of heart disease, ischemia (CAD) and structural heart disease. HeartSciences sits at the forefront of innovation and technological development focused on advancing the field of electrocardiology to provide early heart disease detection. WHO IS HEARTSCIENCES: ? HeartSciences seeks to bridge today’s “diagnostic gap” in cardiac care by providing effective front-line solutions that assist in the detection of heart disease in at-risk patients. ? HeartSciences has invested heavily in research and development focused on advancing the field of electrocardiography through the use of technology to develop new algorithms focused on detecting cardiac conditions not previously available in ECG devices. ? Its first product, the MyoVista? Wavelet ECG (wavECG?) Cardiac Testing Device, is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic dysfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology. LVDD is associated with almost all forms and co-morbidities of heart disease and may include hypertension, diabetes, valvular disease, ischemia, and reduced systolic function, among others.
- 网站
-
https://www.heartsciences.com
HeartSciences (NASDAQ:HSCS)的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Southlake，Texas
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Medical Devices、Heart Disease Screening、Electrophysiology、Diastolic Dysfunction、Ejection Fraction、ECG、12-Lead ECG、MyoVista Informatics、Continuous Wavelet Transform、Wavelet Signal Processing、Cardiac Dysfunction、Wavelet ECG、wavECG、Repolarization Abnormalities和Relaxation Abnormalities
地点
-
主要
获取路线
550 Reserve Street
Suite 360
US，Texas，Southlake，76092
HeartSciences (NASDAQ:HSCS)员工
-
Andy Webber
Director Of Business Development, EMEA - HeartSciences
-
Jason Domask
Director of Software Engineering | Director of Agile Program Management Office
-
Gary Utrup, CMQ-OE
Quality & CM Operations Manager at HeartSciences
-
Tess Jackovich
Bold Executive Business Leader I P&L Impact-ROI I Innovative Product Development, Positioning & Launch I Growth Catalyst I Go-To-Market Roadmaps…
动态
-
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement Approval would allow reimbursement for MyoVista? wavECG algorithm and MyoVista InsightsTM low ejection fraction algorithm, upon FDA clearance. $HSCS #NASDAQ #AI #ECG https://lnkd.in/ddtdeav3
-
-
This article does an exceptional job validating our AI-ECG Cloud strategy! MyoVista Insights(TM) is a cloud-native, patient-centric, AI-enabled ECG reporting and management solution designed to tackle the most critical barriers in adopting AI algorithms for ECG analysis across a wide range of applications. By addressing key challenges—like ensuring robust quality checks, integrating seamlessly with existing clinical workflows, and delivering clear, intuitive presentation of model output—MyoVista Insights breaks down the obstacles that often prevent AI from delivering its full value in clinical settings. We’re excited to lead the way in developing ECG Management systems that prioritize what truly matters to healthcare providers and patients alike! https://lnkd.in/g4vUWNM3 $HSCS #AI #ECG #DigitalHealth #Innovation #HealthcareTech #PatientCentric #CloudComputing #MedicalDevices #artificialintelligence #innovation #machinelearning
-
-
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit Mr. Simpson is scheduled to participate in a fireside chat with analyst Allen Klee at 10:30 a.m. Eastern Time on Thursday, October 17th. $HSCS #NASDAQ #AI #ECG https://lnkd.in/gT-9KSGG
-
-
HeartSciences MyoVista wavECG Technology presented at the UN General Assembly 4th Annual International Digital Health Symposium in New York City! HeartSciences had a unique opportunity to showcase our MoVista? wavECG? Technology during the UN General Assembly on Wednesday September 25th. Mark Hilz (COO) also presented the MyoVista?wavECG Device as part of the 4th Annual International Digital Health Symposium live lab demonstration. #NASDAQ $HSCS #AI #ECG www.heartsciences.com
-
-
Honored to attend a global discussion on AI as part of the UN General Assembly in New York City!??? It was a privilege to represent HeartSciences, Inc. at a prestigious roundtable event, sponsored by the government of Vietnam and leading technology company FPT. This exciting event focused on the role of AI in the evolution of technology solutions and societal ecosystems—healthcare included. In a post-session breakout discussion, we addressed the industry-specific challenges and attributes of AI in healthcare, particularly in patient risk-stratification and clinician decision support, which are key areas of development for HeartSciences’ AI-ECG technology. The roundtable brought together dignitaries from the U.S. and Vietnam, including Vietnam’s newly appointed General Secretary and President H.E. Mr. To Lam, as well as executives from industry leaders like Intel and AMD. We are truly honored to have been invited as innovators and disruptors in the healthcare space and to witness the forward-thinking collaboration between governments and technology companies that is shaping the future of healthcare and diagnostic solutions. Looking forward to leveraging these connections and insights to continue our mission of transforming cardiac diagnostics with AI-powered ECG technology to enhance patient risk-stratification and clinician decision support. Check out some of our moments from the event below! ???? HeartSciences will also have the opportunity to showcase our technology during the UN General Assembly on Wednesday the 25th as Mark Hilz (Chief Operating Officer) will be presenting the MyoVista wavECG Device as part of the Live Lab demonstration https://lnkd.in/gEYBisfS www.heartsciences.com
-
-
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results $HSCS #NASDAQ #AI #ECG https://lnkd.in/gRXcdRwQ See the new website: https://lnkd.in/gY65Y6X4
-
-
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runway Ahead of Upcoming FDA Submission $HSCS #NASDAQ #AI #ECG https://lnkd.in/dnqnXNvv https://heartsciences.com
-
-
Our new website is live! ?? See our AI-ECG solutions to revolutionize cardiac care. Check us out at www.heartsciences.com and discover how we are transforming the early detection of heart disease through AI-ECG technology. $HSCS #NASDAQ #AI #ECG
-
-
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results Company saw a number of major positive developments and resolved several significant challenges. $HSCS #NASDAQ #AI #ECG https://lnkd.in/gFXRamNn www.heartsciences.com
-